Share Price and Basic Stock Data
Last Updated: November 26, 2025, 5:19 pm
| PEG Ratio | 1.17 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jagsonpal Pharmaceuticals Ltd operates in the pharmaceuticals sector, reporting a current price of ₹209 and a market capitalization of ₹1,395 Cr. The company has shown fluctuating sales over the last few quarters, with total sales standing at ₹237 Cr for the fiscal year ending March 2023. The revenue is projected to rise to ₹269 Cr in March 2025, reflecting a growth trajectory. Quarterly sales peaked at ₹75 Cr in September 2024 but dropped to ₹43 Cr in March 2025, indicating seasonal variability in demand. The trailing twelve months (TTM) sales reached ₹283 Cr, which suggests a positive shift in sales performance. This growth is underpinned by a combination of effective product offerings and market conditions that favor pharmaceutical growth in India. However, the company’s operational performance has been inconsistent, as evidenced by the fluctuations in quarterly sales figures, which could influence investor sentiment and market perception.
Profitability and Efficiency Metrics
Jagsonpal Pharmaceuticals reported a net profit of ₹62 Cr with a profit margin of 20.60% for the fiscal year ending March 2025, showcasing robust profitability compared to typical industry standards. The operating profit margin (OPM) was recorded at 19%, reflecting the company’s ability to manage its costs effectively. Additionally, the return on equity (ROE) stood at 18.6%, indicating efficient utilization of shareholder equity to generate profits. The interest coverage ratio (ICR) was exceptionally high at 61.86x, suggesting that the company has no debt obligations impacting its profitability. The cash conversion cycle of 39 days demonstrates efficient management of working capital, enabling the company to convert investments into cash flows quickly. However, the variability in quarterly operating profits, such as a decline to ₹3 Cr in December 2023, may pose challenges in sustaining profitability in the long term.
Balance Sheet Strength and Financial Ratios
Jagsonpal Pharmaceuticals maintains a strong balance sheet, characterized by total reserves of ₹240 Cr and negligible borrowings of ₹9 Cr. This positions the company favorably in terms of financial health, with a debt-to-equity ratio of 0.00, indicating no reliance on external debt financing. The company’s book value per share was reported at ₹36.08 for March 2025, while the price-to-book value (P/BV) ratio stood at 5.99x. This suggests that the stock is trading at a premium, reflecting investor confidence in the company’s future growth prospects. Furthermore, the current ratio of 6.22x indicates strong liquidity, allowing the company to easily meet its short-term obligations. However, the high price-to-earnings (P/E) ratio of 31.9 could signal that the stock is overvalued, limiting upside potential for new investors. The financial ratios indicate a well-capitalized company but raise questions about sustainability at elevated valuation levels.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Jagsonpal Pharmaceuticals reveals a strong promoter holding of 67.54%, which instills confidence in the management’s commitment to the company’s long-term strategy. The presence of Foreign Institutional Investors (FIIs) at 2.12% and Domestic Institutional Investors (DIIs) at 0.08% is relatively low, indicating limited institutional interest. The total number of shareholders has increased to 24,653, reflecting growing public interest in the stock. Over the past year, promoter shareholding has gradually decreased from 68.72% in December 2022 to the current 67.54%, which may raise concerns about potential dilution of control. However, the stable public holding of 30.25% suggests a healthy distribution of shares amongst retail investors, which could provide stability. The shareholding dynamics indicate a generally positive sentiment among retail investors but highlight a need for increased institutional participation to enhance credibility.
Outlook, Risks, and Final Insight
The outlook for Jagsonpal Pharmaceuticals appears cautiously optimistic, given its strong profitability metrics and solid balance sheet. However, the company faces several risks, including fluctuating sales and the potential for increased competition in the pharmaceuticals sector. The inconsistency in quarterly performance could hinder revenue growth and affect investor confidence. Additionally, external factors such as regulatory changes and pricing pressures could impact profitability. On the positive side, the company’s efficient capital management and low debt levels provide a buffer against economic downturns. If the company can stabilize its sales and improve operational consistency, it may enhance its market position and attract more institutional investors. Conversely, failure to address operational inefficiencies could lead to a decline in investor sentiment and stock performance. Overall, Jagsonpal stands at a crossroads where strategic decisions will significantly influence its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Jagsonpal Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 61 | 61 | 60 | 55 | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 |
| Expenses | 53 | 48 | 52 | 50 | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 |
| Operating Profit | 7 | 13 | 9 | 5 | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 |
| OPM % | 12% | 21% | 14% | 10% | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% |
| Other Income | -3 | 1 | 2 | 3 | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 4 | 14 | 10 | 7 | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 |
| Tax % | 24% | 24% | 21% | 24% | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% |
| Net Profit | 3 | 10 | 8 | 6 | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 |
| EPS in Rs | 0.45 | 1.59 | 1.19 | 0.85 | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 |
Last Updated: August 1, 2025, 7:00 pm
Below is a detailed analysis of the quarterly data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 76.00 Cr.. The value appears strong and on an upward trend. It has increased from 59.00 Cr. (Mar 2025) to 76.00 Cr., marking an increase of 17.00 Cr..
- For Expenses, as of Jun 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 50.00 Cr. (Mar 2025) to 61.00 Cr., marking an increase of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Mar 2025) to 19.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 4.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.62. The value appears strong and on an upward trend. It has increased from 0.99 (Mar 2025) to 1.62, marking an increase of 0.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 283 |
| Expenses | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 227 |
| Operating Profit | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 55 |
| OPM % | 7% | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% |
| Other Income | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 34 |
| Interest | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit before tax | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 79 |
| Tax % | 16% | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | |
| Net Profit | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 62 |
| EPS in Rs | 0.32 | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 9.32 |
| Dividend Payout % | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 300.00% | -200.00% | 158.33% | 14.29% | 112.50% | 11.76% | 42.11% | -18.52% | 150.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | 100.00% | -500.00% | 358.33% | -144.05% | 98.21% | -100.74% | 30.34% | -60.62% | 168.52% |
Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 38% |
| 3 Years: | 29% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 75% |
| 3 Years: | 16% |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:00 am
Balance Sheet
Last Updated: November 9, 2025, 2:17 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 240 |
| Borrowings | 36 | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 9 |
| Other Liabilities | 22 | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 37 |
| Total Liabilities | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
| Fixed Assets | 56 | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 90 |
| CWIP | 2 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
| Other Assets | 98 | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 209 |
| Total Assets | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
Below is a detailed analysis of the balance sheet data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 13.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 37.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 299.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 90.00 Cr.. The value appears to be declining and may need further review. It has decreased from 94.00 Cr. (Mar 2025) to 90.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 184.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Sep 2025, the value is 299.00 Cr.. The value appears strong and on an upward trend. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
Notably, the Reserves (240.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -30.00 | -26.00 | -2.00 | -19.00 | 5.00 | 4.00 | 12.00 | 26.00 | 28.00 | 14.00 | 42.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 |
| Inventory Days | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 |
| Days Payable | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 |
| Cash Conversion Cycle | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 |
| Working Capital Days | 64 | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 |
| ROCE % | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 83 | 0.04 | 0 | 83 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.26 | 8.49 | 10.20 | 7.48 | 6.51 |
| Diluted EPS (Rs.) | 8.22 | 8.46 | 10.20 | 7.48 | 6.51 |
| Cash EPS (Rs.) | 9.56 | 9.13 | 10.66 | 8.06 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 46.96 | 43.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 49.95 | 46.54 |
| Dividend / Share (Rs.) | 2.50 | 5.00 | 5.00 | 4.00 | 1.00 |
| Revenue From Operations / Share (Rs.) | 40.47 | 78.94 | 90.36 | 86.30 | 71.74 |
| PBDIT / Share (Rs.) | 8.92 | 12.23 | 15.22 | 11.12 | 8.96 |
| PBIT / Share (Rs.) | 7.70 | 11.61 | 14.76 | 10.54 | 8.76 |
| PBT / Share (Rs.) | 10.52 | 11.30 | 13.29 | 10.43 | 8.35 |
| Net Profit / Share (Rs.) | 8.34 | 8.50 | 10.20 | 7.48 | 6.51 |
| PBDIT Margin (%) | 22.05 | 15.49 | 16.84 | 12.88 | 12.48 |
| PBIT Margin (%) | 19.02 | 14.70 | 16.34 | 12.20 | 12.21 |
| PBT Margin (%) | 25.99 | 14.31 | 14.70 | 12.08 | 11.63 |
| Net Profit Margin (%) | 20.60 | 10.76 | 11.28 | 8.66 | 9.07 |
| Return on Networth / Equity (%) | 23.11 | 11.98 | 16.81 | 15.92 | 14.95 |
| Return on Capital Employeed (%) | 20.26 | 15.50 | 23.10 | 20.55 | 18.54 |
| Return On Assets (%) | 19.89 | 10.34 | 13.70 | 11.62 | 10.38 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Asset Turnover Ratio (%) | 1.08 | 1.01 | 1.30 | 1.36 | 1.21 |
| Current Ratio (X) | 6.22 | 10.42 | 5.97 | 3.24 | 2.98 |
| Quick Ratio (X) | 5.64 | 9.63 | 5.22 | 2.37 | 2.25 |
| Inventory Turnover Ratio (X) | 17.80 | 1.24 | 1.24 | 1.36 | 1.31 |
| Dividend Payout Ratio (NP) (%) | 23.89 | 58.31 | 0.00 | 53.50 | 15.35 |
| Dividend Payout Ratio (CP) (%) | 20.83 | 54.29 | 0.00 | 49.63 | 14.91 |
| Earning Retention Ratio (%) | 76.11 | 41.69 | 0.00 | 46.50 | 84.65 |
| Cash Earning Retention Ratio (%) | 79.17 | 45.71 | 0.00 | 50.37 | 85.09 |
| Interest Coverage Ratio (X) | 61.86 | 39.74 | 96.57 | 102.18 | 21.61 |
| Interest Coverage Ratio (Post Tax) (X) | 38.24 | 28.60 | 74.08 | 69.70 | 16.71 |
| Enterprise Value (Cr.) | 1305.18 | 591.93 | 644.85 | 795.42 | 154.96 |
| EV / Net Operating Revenue (X) | 4.86 | 2.84 | 2.72 | 3.52 | 0.82 |
| EV / EBITDA (X) | 22.02 | 18.30 | 16.17 | 27.31 | 6.60 |
| MarketCap / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| Retention Ratios (%) | 76.10 | 41.68 | 0.00 | 46.49 | 84.64 |
| Price / BV (X) | 5.99 | 3.95 | 4.78 | 6.68 | 1.83 |
| Price / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.02 | 0.08 |
After reviewing the key financial ratios for Jagsonpal Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.00, marking a decrease of 3.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.26. This value is within the healthy range. It has decreased from 8.49 (Mar 24) to 8.26, marking a decrease of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.22. This value is within the healthy range. It has decreased from 8.46 (Mar 24) to 8.22, marking a decrease of 0.24.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.56. This value is within the healthy range. It has increased from 9.13 (Mar 24) to 9.56, marking an increase of 0.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Dividend / Share (Rs.), as of Mar 25, the value is 2.50. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.50, marking a decrease of 2.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 40.47. It has decreased from 78.94 (Mar 24) to 40.47, marking a decrease of 38.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.92. This value is within the healthy range. It has decreased from 12.23 (Mar 24) to 8.92, marking a decrease of 3.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. It has decreased from 11.61 (Mar 24) to 7.70, marking a decrease of 3.91.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.30 (Mar 24) to 10.52, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.34. This value is within the healthy range. It has decreased from 8.50 (Mar 24) to 8.34, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 15.49 (Mar 24) to 22.05, marking an increase of 6.56.
- For PBIT Margin (%), as of Mar 25, the value is 19.02. This value is within the healthy range. It has increased from 14.70 (Mar 24) to 19.02, marking an increase of 4.32.
- For PBT Margin (%), as of Mar 25, the value is 25.99. This value is within the healthy range. It has increased from 14.31 (Mar 24) to 25.99, marking an increase of 11.68.
- For Net Profit Margin (%), as of Mar 25, the value is 20.60. This value exceeds the healthy maximum of 10. It has increased from 10.76 (Mar 24) to 20.60, marking an increase of 9.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 23.11. This value is within the healthy range. It has increased from 11.98 (Mar 24) to 23.11, marking an increase of 11.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.26. This value is within the healthy range. It has increased from 15.50 (Mar 24) to 20.26, marking an increase of 4.76.
- For Return On Assets (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 19.89, marking an increase of 9.55.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.08. It has increased from 1.01 (Mar 24) to 1.08, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 6.22. This value exceeds the healthy maximum of 3. It has decreased from 10.42 (Mar 24) to 6.22, marking a decrease of 4.20.
- For Quick Ratio (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 2. It has decreased from 9.63 (Mar 24) to 5.64, marking a decrease of 3.99.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 17.80. This value exceeds the healthy maximum of 8. It has increased from 1.24 (Mar 24) to 17.80, marking an increase of 16.56.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 58.31 (Mar 24) to 23.89, marking a decrease of 34.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.83. This value is within the healthy range. It has decreased from 54.29 (Mar 24) to 20.83, marking a decrease of 33.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.11. This value exceeds the healthy maximum of 70. It has increased from 41.69 (Mar 24) to 76.11, marking an increase of 34.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.17. This value exceeds the healthy maximum of 70. It has increased from 45.71 (Mar 24) to 79.17, marking an increase of 33.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 61.86. This value is within the healthy range. It has increased from 39.74 (Mar 24) to 61.86, marking an increase of 22.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.24. This value is within the healthy range. It has increased from 28.60 (Mar 24) to 38.24, marking an increase of 9.64.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,305.18. It has increased from 591.93 (Mar 24) to 1,305.18, marking an increase of 713.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.86. This value exceeds the healthy maximum of 3. It has increased from 2.84 (Mar 24) to 4.86, marking an increase of 2.02.
- For EV / EBITDA (X), as of Mar 25, the value is 22.02. This value exceeds the healthy maximum of 15. It has increased from 18.30 (Mar 24) to 22.02, marking an increase of 3.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For Retention Ratios (%), as of Mar 25, the value is 76.10. This value exceeds the healthy maximum of 70. It has increased from 41.68 (Mar 24) to 76.10, marking an increase of 34.42.
- For Price / BV (X), as of Mar 25, the value is 5.99. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.99, marking an increase of 2.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jagsonpal Pharmaceuticals Ltd:
- Net Profit Margin: 20.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.26% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 23.11% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 38.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.9 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Innov8 3rd Floor, New Delhi Delhi 110020 | cs@jagsonpal.com http://www.jagsonpal.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajpal Singh Kochhar | Chairman Emeritus |
| Mr. Harsha Raghavan | Chairman & Non-Exe.Director |
| Mr. Manish Gupta | Managing Director |
| Mr. Prithipal Singh Kochhar | Non Executive Director |
| Mr. Debasis Bikash Nandy | Independent Director |
| Ms. Radhika Madhukar Dudhat | Independent Director |
| Ms. Pallavi Dinodia Gupta | Independent Director |
FAQ
What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's intrinsic value (as of 27 November 2025) is 176.87 which is 12.87% lower the current market price of 203.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,353 Cr. market cap, FY2025-2026 high/low of 328/193, reserves of ₹240 Cr, and liabilities of 299 Cr.
What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?
The Market Cap of Jagsonpal Pharmaceuticals Ltd is 1,353 Cr..
What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 27 November 2025?
The current stock price of Jagsonpal Pharmaceuticals Ltd as on 27 November 2025 is 203.
What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is 328/193.
What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?
The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 30.9.
What is the Book Value of Jagsonpal Pharmaceuticals Ltd?
The Book Value of Jagsonpal Pharmaceuticals Ltd is 38.0.
What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?
The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 1.23 %.
What is the ROCE of Jagsonpal Pharmaceuticals Ltd?
The ROCE of Jagsonpal Pharmaceuticals Ltd is 23.0 %.
What is the ROE of Jagsonpal Pharmaceuticals Ltd?
The ROE of Jagsonpal Pharmaceuticals Ltd is 18.6 %.
What is the Face Value of Jagsonpal Pharmaceuticals Ltd?
The Face Value of Jagsonpal Pharmaceuticals Ltd is 2.00.